Preclinical: new 3-in-1 ADC with a completely different approach is ready to move to clinical stage

[Maxone73]

Not clinical yet, but pan-cancer approach, in a market (ADCs market) that is ramping up, so we can expect news soon!

This article discusses a promising new cancer treatment using a 3-in-1 antibody design. This new technology seeks to overcome the limitations of current immunotherapy methods by combining precision targeting of cancer cells, enhanced drug delivery, and immune system activation.

The antibody utilizes neoantigens—unique mutations found in cancer cells—to help the immune system recognize and attack tumors.

Preclinical studies in mice have shown promising results, including extended survival and even complete remission at higher doses. Researchers are ready to move into clinical phase.

prostatewarriors.com/2024/1...

[petabyte]

Hi Maxone73

I really appreciate these posts. It's nice to know that so many people are working on this disease and, who knows, maybe a cure or better treatments can be found and help us all.

Thanks!